Special Issue "From Antibody Fragments to Therapeutic Manufacturing: Challenges and the Future of Antibody Synthesis"

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (20 July 2021) | Viewed by 668

Special Issue Editors

Macromoltek, Inc., 2500 W William Cannon Dr, Suite 204, Austin, TX 78745, USA
Interests: antibody discovery; antibody structure prediction and analysis; protein mutational analysis; antibody design; protein design; deep learning; machine learning; structural biology
Prof. Dr. Robert H. Carnahan
E-Mail Website
Guest Editor
1. The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 27232, USA
2. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 27232, USA
Interests: antibody therapeutics; infectious diseases; viruses; antibody generation and development; biomarker development; assay design; cancer biology; cell biology; recombinant mammalian and bacterial protein expression and purification; antibody purification; biotechnology; molecular biology

Special Issue Information

Dear Colleagues,

With the explosive growth in the antibody therapeutics market comes the increasing need to create higher-quality antibody proteins using time- and cost-effective strategies. Protein synthesis is a rapidly evolving field with a broad diversity of techniques. Antibody protein synthesis, particularly, requires constant innovation to create better research tools, diagnostics, and therapeutics. Expression systems, scale, and techniques vary widely from recombinant expression in prokaryotes to mammalian cell culture expression, cell-free expression, monoclonal vs. polyclonal, fragments, isotypes, multi-specifics, library generation, and many others.

The Special Issue “Form Antibody Fragments to Therapeutic Manufacturing: Challenges and the Future of Antibody Synthesis” aims to kindle discussion of current and innovative methods of antibody production. We invite experts to share manuscripts describing their choice of antibody synthesis method, advantages, disadvantages, and innovations from preclinical proof-of-concept to large-scale manufacturing of antibody or antibody-like proteins intended for research, diagnostics, or therapeutic applications. 

Dr. Monica Berrondo
Prof. Dr. Robert H. Carnahan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Antibody fragment
  • Antibody expression
  • Multi-specific antibodies
  • Cell-free protein synthesis
  • Therapeutic manufacturing
  • Immunization
  • Therapeutics
  • Diagnostics

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop